Patents by Inventor Olivier Rogel

Olivier Rogel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ArylSulfonamide-based matrix metalloprotease inhibitors
    Patent number: 9822092
    Abstract: The present invention provides a compound of formula (I): said compound is inhibitor of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12, and/or MMP-13. Finally, the present invention also provides a pharmaceutical composition.
    Type: Grant
    Filed: October 7, 2014
    Date of Patent: November 21, 2017
    Assignee: NOVARTIS AG
    Inventors: Claus Ehrhardt, Leslie Wighton McQuire, Pascal Rigollier, Olivier Rogel, Michael David Shultz, Ruben Alberto Tommasi
  • Complement pathway modulators and uses thereof
    Patent number: 9815819
    Abstract: The present invention provides a compound of formula I: (I) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: June 27, 2013
    Date of Patent: November 14, 2017
    Assignee: NOVARTIS AG
    Inventors: Eva Altmann, Ulrich Hommel, Edwige Liliane Jeanne Lorthiois, Jeurgen Klaus Maibaum, Nils Ostermann, Jean Quancard, Stefan Andreas Randl, Olivier Rogel, Anna Vulpetti
  • Complement pathway modulators and uses thereof
    Patent number: 9550755
    Abstract: The present invention provides a compound of formula I: a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: June 27, 2013
    Date of Patent: January 24, 2017
    Assignee: NOVARTIS AG
    Inventors: Ulrich Hommel, Edwige Liliane Jeanne Lorthiois, Jeurgen Klaus Maibaum, Nils Ostermann, Stefan Andreas Randl, Olivier Rogel, Anna Vulpetti
  • Complement pathway modulators and uses thereof
    Patent number: 9487483
    Abstract: The present invention provides a compound of formula (I): a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: June 27, 2013
    Date of Patent: November 8, 2016
    Assignee: Novartis AG
    Inventors: Eva Altmann, Ulrich Hommel, Edwige Liliane Jeanne Lorthiois, Jeurgen Klaus Maibaum, Nils Ostermann, Jean Quancard, Stefan Andreas Randl, Olivier Rogel, Anna Vulpetti, Stefanie Flohr
  • Pyrrolidine derivatives and their use as complement pathway modulators
    Patent number: 9468661
    Abstract: The present invention provides a compound of formula (I) a method for manufacturing the compounds of the invention, and its therapeutic uses as complement pathway modulators for the treatment of ocular diseases. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: June 27, 2013
    Date of Patent: October 18, 2016
    Assignee: Novartis AG
    Inventors: Eva Altmann, Ulrich Hommel, Edwige Liliane Jeanne Lorthiois, Jeurgen Klaus Maibaum, Nils Ostermann, Jean Quancard, Stefan Andreas Randl, Olivier Rogel, Anna Vulpetti
  • Pyrrolidine derivatives and their use as complement pathway modulators
    Patent number: 9464081
    Abstract: The present invention provides a compound of formula (I) a method for manufacturing the compounds of the invention, and its therapeutic uses as a factor D inhibitor for the treatment of ophthalmic diseases. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: June 27, 2013
    Date of Patent: October 11, 2016
    Assignee: Novartis AG
    Inventors: Stefanie Flohr, Ulrich Hommel, Edwige Liliane Jeanne Lorthiois, Jeurgen Klaus Maibaum, Nils Ostermann, Jean Quancard, Stefan Andreas Randl, Olivier Rogel, Anna Vulpetti
  • Pyrrolidine derivatives and their use as complement pathway modulators
    Patent number: 9388199
    Abstract: The present invention provides a compound of formula (I) a method for manufacturing the compounds of the invention and its therapeutic uses as complement pathway modulators for the treatment of ocular diseases. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: June 27, 2013
    Date of Patent: July 12, 2016
    Assignee: NOVARTIS AG
    Inventors: Eva Altmann, Ulrich Hommel, Edwige Liliane Jeanne Lorthiois, Jeurgen Klaus Maibaum, Nils Ostermann, Stefan Andreas Randl, Olivier Rogel, Anna Vulpetti
  • Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof
    Publication number: 20160145247
    Abstract: The present invention provides a compound of formula (I), a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: July 17, 2014
    Publication date: May 26, 2016
    Applicant: NOVARTIS AG
    Inventors: David B. BELANGER, Stefanie FLOHR, Christine Fang GELIN, Keith JENDZA, Nan JI, Donglei LIU, Edwige Lilliane Jeanne LORTHIOIS, Rakeshri Ganesh KARKI, Nello MAINOLFI, James J. POWERS, Stefan Andreas RANDL, Olivier ROGEL, Anna VULPETTI, Taeyoung YOON
  • PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS
    Publication number: 20150322060
    Abstract: The present invention provides a compound of formula (I) a method for manufacturing the compounds of the invention, and its therapeutic uses as a factor D inhibitor for the treatment of ophthalmic diseases. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: June 27, 2013
    Publication date: November 12, 2015
    Applicant: NOVARTIS AG
    Inventors: Stefanie FLOHR, Ulrich HOMMEL, Edwige Liliane Jeanne LORTHIOIS, Jeurgen Klaus MAIBAUM, Nils OSTERMANN, Jean QUANCARD, Stefan Andreas RANDL, Olivier ROGEL, Anna VULPETTI
  • PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS
    Publication number: 20150191462
    Abstract: The present invention provides a compound of formula I: (I) a method for manufacturing the compounds of the invention, and its therapeutic uses as complement alternative inhibitors for the treatment of ocular diseases. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: June 27, 2013
    Publication date: July 9, 2015
    Applicant: NOVARTIS AG
    Inventors: Ulrich Hommel, Edwige Liliane Jeanne Lorthiois, Jeurgen Klaus Maibaum, Nils Ostermann, Stefan Andreas Randl, Olivier Rogel, Anna Vulpetti
  • PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS
    Publication number: 20150190457
    Abstract: The present invention provides a compound of formula (I) a method for manufacturing the compounds of the invention, and its therapeutic uses as complement pathway modulators for the treatment of ocular diseases. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: June 27, 2013
    Publication date: July 9, 2015
    Applicant: NOVARTIS AG
    Inventors: Eva Altmann, Ulrich Hommel, Edwige Liliane Jeanne Lorthiois, Jeurgen Klaus Maibaum, Nils Ostermann, Jean Quancard, Stefan Andreas Randl, Olivier Rogel, Anna Vulpetti
  • PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS
    Publication number: 20150166578
    Abstract: The present invention provides a compound of formula (I) a method for manufacturing the compounds of the invention and its therapeutic uses as complement pathway modulators for the treatment of ocular diseases. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: June 27, 2013
    Publication date: June 18, 2015
    Applicant: NOVARTIS AG
    Inventors: Eva Altmann, Ulrich Hommel, Edwige Liliane Jeanne Lorthiois, Jeurgen Klaus Maibaum, Nils Ostermann, Stefan Andreas Randl, Olivier Rogel, Anna Vulpetti
  • COMPLEMENT PATHWAY MODULATORS AND USES THEREOF
    Publication number: 20150148349
    Abstract: The present invention provides a compound of formula (I): a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: June 27, 2013
    Publication date: May 28, 2015
    Applicant: NOVARTIS AG
    Inventors: Eva Altmann, Ulrich Hommel, Edwige Liliane Jeanne Lorthiois, Jeurgen Klaus Maibaum, Nils Ostermann, Jean Quancard, Stefan Andreas Randl, Olivier Rogel, Anna Vulpetti
  • COMPLEMENT PATHWAY MODULATORS AND USES THEREOF
    Publication number: 20150148374
    Abstract: The present invention provides a compound of formula I: a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: June 27, 2013
    Publication date: May 28, 2015
    Applicant: NOVARTIS AG
    Inventors: Ulrich Hommel, Edwige Liliane Jeanne Lorthiois, Jeurgen Klaus Maibaum, Nils Ostermann, Stefan Andreas Randl, Olivier Rogel, Anna Vulpetti
  • COMPLEMENT PATHWAY MODULATORS AND USES THEREOF
    Publication number: 20150141455
    Abstract: The present invention provides a compound of formula I: (I) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: June 27, 2013
    Publication date: May 21, 2015
    Applicant: NOVARTIS AG
    Inventors: Eva Altmann, Ulrich Hommel, Edwige Liliane Jeanne Lorthiois, Jeurgen Klaus Maibaum, Nils Ostermann, Jean Quancard, Stefan Andreas Randl, Olivier Rogel, Anna Vulpetti
  • Arylsulfonamide based matrix metalloprotease inhibitors
    Patent number: 8975439
    Abstract: The present invention provides a compound of formula (I): said compound is inhibitor of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12, and/or MMP-13. Finally, the present invention also provides a pharmaceutical composition.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: March 10, 2015
    Assignee: Novartis AG
    Inventors: Ruben Alberto Tommasi, Michael David Shultz, Leslie Wighton McQuire, Pascal Rigollier, Olivier Rogel, Claus Ehrhardt
  • ArylSulfonamide-Based Matrix Metalloprotease Inhibitors
    Publication number: 20150045398
    Abstract: The present invention provides a compound of formula (I): said compound is inhibitor of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12, and/or MMP-13. Finally, the present invention also provides a pharmaceutical composition.
    Type: Application
    Filed: October 7, 2014
    Publication date: February 12, 2015
    Applicant: NOVARTIS AG
    Inventors: Claus EHRHARDT, Leslie Wighton MCQUIRE, Pascal RIGOLLIER, Olivier ROGEL, Michael David SHULTZ, Ruben Alberto TOMMASI
  • SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS
    Publication number: 20140031399
    Abstract: The present invention provides a compound of formula (I): said compound is inhibitor of MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-12 and/or MMP-13. Finally, the present invention also provides pharmaceutical composition that include the compound of formula (I).
    Type: Application
    Filed: September 30, 2013
    Publication date: January 30, 2014
    Inventors: Leslie Wighton MCQUIRE, Olivier ROGEL, Michael SHULTZ, Ruben Alberto TOMMASI, Sven WEILER
  • Arylsulfonamide based matrix metalloprotease inhibitors
    Patent number: 8362063
    Abstract: The present invention provides a compound of formula (I): said compound is inhibitor of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12, and/or MMP-13. Finally, the present invention also provides a pharmaceutical composition.
    Type: Grant
    Filed: May 29, 2012
    Date of Patent: January 29, 2013
    Assignee: Novartis AG
    Inventors: Ruben Alberto Tommasi, Michael Shultz, Leslie Wighton McQuire, Pascal Rigollier, Olivier Rogel, Claus Ehrhardt
  • Complement pathway modulators and uses thereof
    Publication number: 20120295884
    Abstract: The present invention provides a compound of formula I: a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: January 2, 2012
    Publication date: November 22, 2012
    Applicant: NOVARTIS AG
    Inventors: Eva ALTMANN, Ulrich HOMMEL, Edwige Liliane Jeanne LORTHIOIS, Juergen Klaus MAIBAUM, Nils OSTERMANN, Jean Quancard, Stefan Andreas RANDL, Olivier ROGEL, Oliver SIMIC, Anna VULPETTI, Veronique Stark-Rogel